Abstract: The present invention concerns compounds comprising, within short sequences from a specific region of the kinase, that can modulate kinase-associated signal transduction.

Abstract: Peptides which are peptide derivatives of the A region of a protein kinase can modulate the activity of protein kinases. The activity of a protein kinase in a subject can be modulated by administering one or more of these peptides.

Abstract: Disclosed are peptides which are peptide derivatives of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.

Abstract: Disclosed is a method for modulating metabolism in an individual. The method includes administering to the individual a substance, such as a GRK-derived HJ loop peptide, which alters activity of a GRK, wherein the administration of the substance results in an increase or decrease of the individual's metabolism. Also disclosed are GRK-derived HJ loop peptides.

Abstract: Prostate cancer can be treated by administering one or more inhibitros of lyn tyrosine kinase to an individual who has or is susceptible to contracting prostate cancer. The inhibitors include peptides containing between six and eleven amino acids.

Abstract: Disclosed are novel multivalent ligands represented by the following structural formula: B is a multilinker backbone. n is an integer from two to about twenty. Each L is a covalent bond or linking group. Each P is a peptide having from about 10 to about 30 amino acid residues. At least two of the peptides P are a peptide derivative of an AHR of an angiogenic protein, a hybrid peptide, a peptide derivative of a hybrid peptide or a combination thereof. Each peptide and each linker or covalent bond is independently chosen. The disclosed multivalent ligands can be used to modulate angiogenesis in a mammal. Also disclosed are novel peptide derivatives of an AHR of an angiogenic protein, novel hybrid peptides, peptide derivatives of the novel hybrid peptides and polypeptide multivalent ligands thereof.

Abstract: Disclosed are peptides which are peptide derivatives of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.

Abstract: Disclosed are novel multivalent ligands represented by the following structural formula: ##STR1## B is a multilinker backbone. n is an integer from two to about twenty.Each L is a covalent bond or linking group.Each P is a peptide having from about 10 to about 30 amino acid residues. At least two of the peptides P are a peptide derivative of an AHR of an angiogenic protein, a hybrid peptide, a peptide derivative of a hybrid peptide or a combination thereof. Each peptide and each linker or covalent bond is independently chosen. The disclosed multivalent ligands can be used to modulate angiogenesis in a mammal.Also disclosed are novel peptide derivatives of an AHR of an angiogenic protein, novel hybrid peptides, peptide derivatives of the novel hybrid peptides and polypeptide multivalent ligands thereof.

Abstract: A biologically active polymeric compound comprising an alkylaryl or heteroalkylaryl backbone having about 5 to about 50 repeating aromatic ring-containing units and which, according to the computer program marketed as SYBYL.RTM. version 5.2 running on a DEC VAX.RTM. 11/750 computer, is capable of forming a linear backbone having a helical secondary structure, and wherein the maximum diameter of the helical structure, as measured by the alkylaryl or heteroalkylaryl backbone, is less than 3 times greater than the maximum diameter of the aryl group of the alkylaryl or heteroalkylaryl backbone.

Abstract: This invention relates to aromatic oligomeric compounds useful in the treatment of cardiovascular, bone metabolic, hypolipidaemic, neuronal, gastrointestinal and elastase-mediated connective tissue degradation disorders and disorders which may be treated by agents effective in binding DNA, to processes for preparation of such oligomeric compounds, to pharmaceutical compositions including such oligomeric compounds, and to their use in the treatment of such disorders.

Abstract: The present invention relates to the aluminum hydroxide having a specific surface area of at least 350 m.sup.2, preferably at least 400 m.sup.2, per g. and to a process for its preparation. The aluminum hydroxide should be capable of absorbing at least 1 g of fat per g. of material. The aluminum hydroxide is preferably part of a pharmaceutical preparation.

Abstract: The present invention relates to the aluminum hydroxide having a specific surface area of at least 350 m.sup.2, preferably at least 400 m.sup.2, per g. and to a process for its preparation. The aluminum hydroxide should be capable of absorbing at least 1 g of fat per g. of material. The aluminum hydroxide is preferably part of a pharmaceutical preparation.